11/14
08:15 am
aura
Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
Medium
Report
Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.
11/12
04:05 pm
aura
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
Medium
Report
Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
10/21
03:13 pm
aura
Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value [Seeking Alpha]
Neutral
Report
Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value [Seeking Alpha]
10/18
03:33 pm
aura
Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at Cowen Inc.
Low
Report
Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at Cowen Inc.
10/18
11:53 am
aura
Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at Scotiabank from $20.00 to $23.00. They now have a "sector outperform" rating on the stock.
Low
Report
Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at Scotiabank from $20.00 to $23.00. They now have a "sector outperform" rating on the stock.
10/18
11:01 am
aura
Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at BTIG Research from $21.00 to $24.00. They now have a "buy" rating on the stock.
Low
Report
Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at BTIG Research from $21.00 to $24.00. They now have a "buy" rating on the stock.
10/18
08:33 am
aura
Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at HC Wainwright from $21.00 to $22.00. They now have a "buy" rating on the stock.
Low
Report
Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at HC Wainwright from $21.00 to $22.00. They now have a "buy" rating on the stock.
10/17
04:05 pm
aura
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
High
Report
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
10/4
08:16 am
aura
Aura Biosciences, Inc. (NASDAQ:AURA) is a favorite amongst institutional investors who own 58% [Yahoo! Finance]
Low
Report
Aura Biosciences, Inc. (NASDAQ:AURA) is a favorite amongst institutional investors who own 58% [Yahoo! Finance]
9/20
03:36 pm
aura
Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream + [Seeking Alpha]
Medium
Report
Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream + [Seeking Alpha]
9/18
07:28 am
aura
Aura Biosciences, Inc. (NASDAQ: AURA) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Medium
Report
Aura Biosciences, Inc. (NASDAQ: AURA) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
9/13
11:19 am
aura
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study [Yahoo! Finance]
Low
Report
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study [Yahoo! Finance]
9/13
08:02 am
aura
Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
9/13
08:02 am
aura
Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at JMP Securities from $19.00 to $23.00. They now have a "market outperform" rating on the stock.
Low
Report
Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at JMP Securities from $19.00 to $23.00. They now have a "market outperform" rating on the stock.
9/12
08:17 am
aura
Aura Bio gains after mid-stage data for lead asset in ocular cancer [Seeking Alpha]
Low
Report
Aura Bio gains after mid-stage data for lead asset in ocular cancer [Seeking Alpha]
9/12
06:30 am
aura
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Low
Report
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
9/11
07:57 am
aura
Aura Biosciences, Inc. (NASDAQ: AURA) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Low
Report
Aura Biosciences, Inc. (NASDAQ: AURA) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
9/4
07:32 am
aura
We're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate [Yahoo! Finance]
Medium
Report
We're Not Very Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Rate [Yahoo! Finance]
9/3
04:05 pm
aura
Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024
Medium
Report
Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024
8/28
04:05 pm
aura
Aura Biosciences to Participate in Upcoming Investor Conferences
Low
Report
Aura Biosciences to Participate in Upcoming Investor Conferences
8/28
11:05 am
aura
Aura Biosciences, Inc. (NASDAQ: AURA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $19.00 price target on the stock.
Low
Report
Aura Biosciences, Inc. (NASDAQ: AURA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $19.00 price target on the stock.
8/26
04:05 pm
aura
Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting
Low
Report
Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting